Compare Grab Holdings Ltd. (GRAB) vs Novavax Inc (NVAX) Price & Performance

GRAB trades at $3.715, down 2.24% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from previous losses. Revenue grew to $3.37B in 2025, with strong analyst consensus of 11 buys versus 1 sell. Recent news includes CEO share sales and Uber CEO's board departure, creating some investor uncertainty despite positive earnings beats.

GRAB presents a compelling turnaround story with recent profitability and strong growth prospects in Southeast Asian markets. The stock trades at a discount to the $5.45 consensus target, offering 47% upside potential. Key risks include competitive pressures, execution challenges in expanding financial services, and insider selling activity. The company's improving cash flow and debt management support the bullish analyst outlook.

Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.

The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.